Cargando…
CDDO-Me: A Novel Synthetic Triterpenoid for the Treatment of Pancreatic Cancer
Pancreatic ductal adenocarcinoma (PDA) is one of the most lethal human malignancy with dismal prognosis and few effective therapeutic options. Novel agents that are safe and effective are urgently needed. Oleanolic acid-derived synthetic triterpenoids are potent antitumorigenic agents, but their eff...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3143824/ https://www.ncbi.nlm.nih.gov/pubmed/21799944 http://dx.doi.org/10.3390/cancers2041779 |
_version_ | 1782208929816641536 |
---|---|
author | Deeb, Dorrah Gao, Xiaohua Arbab, Ali S. Barton, Kenneth Dulchavsky, Scott A. Gautam, Subhash C. |
author_facet | Deeb, Dorrah Gao, Xiaohua Arbab, Ali S. Barton, Kenneth Dulchavsky, Scott A. Gautam, Subhash C. |
author_sort | Deeb, Dorrah |
collection | PubMed |
description | Pancreatic ductal adenocarcinoma (PDA) is one of the most lethal human malignancy with dismal prognosis and few effective therapeutic options. Novel agents that are safe and effective are urgently needed. Oleanolic acid-derived synthetic triterpenoids are potent antitumorigenic agents, but their efficacy or the mechanism of action for pancreatic cancer has not been adequately investigated. In this study, we evaluated the antitumor activity and the mechanism of action of methyl-2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oate (CDDO-Me), a oleanane-derived synthetic triterpenoid for human pancreatic cancer cell lines. CDDO-Me inhibited the growth of both K-ras mutated (MiaPaca2, Panc1 and Capan2) and wild-type K-ras (BxPC3) pancreatic cancer cells at very low concentrations. The growth inhibitory activity of CDDO-Me was attributed to the induction of apoptosis characterized by increased annexin-V-FITC binding and cleavage of PARP-1 and procaspases-3, -8 and-9. In addition, CDDO-Me induced the loss of mitochondrial membrane potential and release of cytochrome C. The antitumor activity of CDDO-Me was associated with the inhibition of prosurvival p-Akt, NF-κB and mammalian target of rapamycin (mTOR) signaling proteins and the downstream targets of Akt and mTOR, such as p-Foxo3a (Akt) and p-S6K1, p-eIF-4E and p-4E-BP1 (mTOR). Silencing of Akt or mTOR with gene specific-siRNA sensitized the pancreatic cancer cells to CDDO-Me, demonstrating Akt and mTOR as molecular targets of CDDO-Me for its growth inhibitory and apoptosis-inducing activity. |
format | Online Article Text |
id | pubmed-3143824 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2010 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-31438242011-07-26 CDDO-Me: A Novel Synthetic Triterpenoid for the Treatment of Pancreatic Cancer Deeb, Dorrah Gao, Xiaohua Arbab, Ali S. Barton, Kenneth Dulchavsky, Scott A. Gautam, Subhash C. Cancers (Basel) Article Pancreatic ductal adenocarcinoma (PDA) is one of the most lethal human malignancy with dismal prognosis and few effective therapeutic options. Novel agents that are safe and effective are urgently needed. Oleanolic acid-derived synthetic triterpenoids are potent antitumorigenic agents, but their efficacy or the mechanism of action for pancreatic cancer has not been adequately investigated. In this study, we evaluated the antitumor activity and the mechanism of action of methyl-2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oate (CDDO-Me), a oleanane-derived synthetic triterpenoid for human pancreatic cancer cell lines. CDDO-Me inhibited the growth of both K-ras mutated (MiaPaca2, Panc1 and Capan2) and wild-type K-ras (BxPC3) pancreatic cancer cells at very low concentrations. The growth inhibitory activity of CDDO-Me was attributed to the induction of apoptosis characterized by increased annexin-V-FITC binding and cleavage of PARP-1 and procaspases-3, -8 and-9. In addition, CDDO-Me induced the loss of mitochondrial membrane potential and release of cytochrome C. The antitumor activity of CDDO-Me was associated with the inhibition of prosurvival p-Akt, NF-κB and mammalian target of rapamycin (mTOR) signaling proteins and the downstream targets of Akt and mTOR, such as p-Foxo3a (Akt) and p-S6K1, p-eIF-4E and p-4E-BP1 (mTOR). Silencing of Akt or mTOR with gene specific-siRNA sensitized the pancreatic cancer cells to CDDO-Me, demonstrating Akt and mTOR as molecular targets of CDDO-Me for its growth inhibitory and apoptosis-inducing activity. MDPI 2010-10-13 /pmc/articles/PMC3143824/ /pubmed/21799944 http://dx.doi.org/10.3390/cancers2041779 Text en © 2013 by the authors; licensee MDPI, Basel, Switzerland. http://creativecommons.org/licenses/by/3.0/ This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/). |
spellingShingle | Article Deeb, Dorrah Gao, Xiaohua Arbab, Ali S. Barton, Kenneth Dulchavsky, Scott A. Gautam, Subhash C. CDDO-Me: A Novel Synthetic Triterpenoid for the Treatment of Pancreatic Cancer |
title | CDDO-Me: A Novel Synthetic Triterpenoid for the Treatment of Pancreatic Cancer |
title_full | CDDO-Me: A Novel Synthetic Triterpenoid for the Treatment of Pancreatic Cancer |
title_fullStr | CDDO-Me: A Novel Synthetic Triterpenoid for the Treatment of Pancreatic Cancer |
title_full_unstemmed | CDDO-Me: A Novel Synthetic Triterpenoid for the Treatment of Pancreatic Cancer |
title_short | CDDO-Me: A Novel Synthetic Triterpenoid for the Treatment of Pancreatic Cancer |
title_sort | cddo-me: a novel synthetic triterpenoid for the treatment of pancreatic cancer |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3143824/ https://www.ncbi.nlm.nih.gov/pubmed/21799944 http://dx.doi.org/10.3390/cancers2041779 |
work_keys_str_mv | AT deebdorrah cddomeanovelsynthetictriterpenoidforthetreatmentofpancreaticcancer AT gaoxiaohua cddomeanovelsynthetictriterpenoidforthetreatmentofpancreaticcancer AT arbabalis cddomeanovelsynthetictriterpenoidforthetreatmentofpancreaticcancer AT bartonkenneth cddomeanovelsynthetictriterpenoidforthetreatmentofpancreaticcancer AT dulchavskyscotta cddomeanovelsynthetictriterpenoidforthetreatmentofpancreaticcancer AT gautamsubhashc cddomeanovelsynthetictriterpenoidforthetreatmentofpancreaticcancer |